ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 8.24 | 0.04 | -0.44 | 0.20 |
| FCF Yield | 0.00% | 0.59% | -0.99% | -1.03% |
| EV / EBITDA | -187.51 | -75.80 | 165.68 | -74.09 |
| Quality | ||||
| ROIC | -21.18% | -25.88% | 6.78% | -23.93% |
| Gross Margin | 90.74% | 91.06% | 98.17% | 84.37% |
| Cash Conversion Ratio | – | -0.43 | -2.17 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | 289.63% | 254.64% | 247.57% | 172.56% |
| Free Cash Flow Growth | -100.00% | 163.43% | -0.32% | 10.51% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | -0.82 | 2.61 | -1.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.52 | 2.13 | 1.41 | 0.77 |
| Cash Conversion Cycle | -427.45 | -490.95 | -339.29 | -223.16 |